Skip to primary navigation
Skip to main content
Skip to footer

Neurotech International

ASX:NTI

Home
Corporate
Development Programs
Investors
Contact

Neurotech says NTI164 shows positive tolerability in key preclinical toxicology studies

5 May 2025 News & Media

Read the full article here.

Footer

Suite 102 / Level 1, 55 Collins Street
Melbourne VIC 3000
Australia

moc.l1775632654anoit1775632654anret1775632654nihce1775632654torue1775632654n@ofn1775632654i1775632654

+61 (3) 9498 3132

Subscribe to our latest announcements

"*" indicates required fields

Name*

First Last

Email*

Name

This field is for validation purposes and should be left unchanged.

Copyright © 2026 Neurotech International • Site by White Noise Communications

Download prospectus